[
{"id":"1","list":"After Market Movers","nullFlag":"","symbol": "OCUL","name": "Ocular Therapeutix I","price": 8.725000000000001,"dollarChange": 0.005000,"percentChange": 0.057339,"time":2.0,"oneDayNull":"0","oneDay": "http://automatedinvestmentresearch.com/OCUL-1d.php","oneMonth": "http://automatedinvestmentresearch.com/OCUL-1mo.php","threeMonthNull":"0","threeMonth": "http://automatedinvestmentresearch.com/OCUL-3mo.php","sixMonthNull":"0","sixMonth": "http://automatedinvestmentresearch.com/OCUL-6mo.php","oneYearNull":"0","oneYear": "http://automatedinvestmentresearch.com/OCUL-1yr.php","open": 8.53,"high": 8.77,"low":8.1601,"volume": 669649,"avgVol": 1139258.666667,"sharesShort": 5936253,"shortPercent": 24.455411,"marketCap": 210046577,"float": 24273781,"headlines":{"data":[{"title":"Edited Transcript of OCUL earnings conference call or presentation 10-Mar-17 1:30pm GMT","publication_date":"2017-03-10 23:25:01 +0000","url":"http://finance.yahoo.com/news/edited-transcript-ocul-earnings-conference-232501843.html","summary":"Edited Transcript of OCUL earnings conference call or presentation 10-Mar-17 1:30pm GMT"},{"title":"Ocular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today","publication_date":"2017-03-10 13:30:00 +0000","url":"http://biz.yahoo.com/cc/6/156066.html","summary":"Ocular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today"},{"title":"Ocular Therapeutix reports 4Q loss","publication_date":"2017-03-10 12:58:38 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-4q-loss-125838717.html","summary":"Ocular Therapeutix reports 4Q loss"},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E","publication_date":"2017-03-10 12:36:55 +0000","url":"http://biz.yahoo.com/e/170310/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"},{"title":"Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results","publication_date":"2017-03-10 12:30:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-reports-fourth-quarter-123000593.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative drug products using its proprietary hydrogel platform technology for the treatment of diseases and conditions of the eye, today announced financial results for the fourth quarter of 2016 and the twelve months ended December 31, 2016."},{"title":"Q4 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open","publication_date":"2017-03-10 12:07:05 +0000","url":"http://biz.yahoo.com/research/earncal/20170310.html?t=ocul","summary":"Q4 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open"},{"title":"Pre-Market Earnings Report for March 10, 2017 : MTN, PGEM, GCO, BKE, HIBB, TGLS, SRLP, CTRN, OCUL, KIRK, CNTY, VNRX","publication_date":"2017-03-09 21:13:15 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NuG215VVAHE/pre-market-earnings-report-for-march-10-2017-mtn-pgem-gco-bke-hibb-tgls-srlp-ctrn-ocul-kirk-cnty-vnrx-cm758814","summary":"The following companies are expected to report earnings prior to market open on 03 10 2017 Visit our Earnings Calendar for a full list of expected earnings releases Vail Resorts Inc MTN is reporting for the quarter ending January 31 2017 The"},{"title":"Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results","publication_date":"2017-03-08 14:00:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-report-fourth-quarter-140000748.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, on Friday, March 10, 2017."},{"title":"Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS)","publication_date":"2017-02-23 18:11:46 +0000","url":"http://www.insidermonkey.com/blog/biotech-movers-and-shakers-ocular-therapeutix-inc-ocul-and-argos-therapeutics-inc-args-561892/","summary":"Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS)"},{"title":"Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain","publication_date":"2017-02-23 13:15:00 +0000","url":"http://finance.yahoo.com/news/blog-coverage-ocular-therapeutix-announced-131500482.html","summary":"[Accesswire] - Upcoming AWS Coverage on Alnylam Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / February 23, 2017 / Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. (NASDAQ: ..."},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events","publication_date":"2017-02-22 13:11:15 +0000","url":"http://biz.yahoo.com/e/170222/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events"},{"title":"8:05 am Ocular Therapeutix announces that the NDA resubmission for DEXTENZA 0.4 mg for intracanalicular use, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review by the FDA","publication_date":"2017-02-22 13:05:00 +0000","url":"http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#ocul","summary":"8:05 am Ocular Therapeutix announces that the NDA resubmission for DEXTENZA 0.4 mg for intracanalicular use, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review by the FDA"},{"title":"Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery","publication_date":"2017-02-22 13:00:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-announces-fda-acceptance-130000286.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company’s New Drug Application resubmission for DEXTENZA™ 0.4 mg for intracanalicular use, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review by the U.S...."},{"title":"Why Ocular Therapeutix Inc Jumped Higher Today","publication_date":"2017-02-10 23:18:13 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JlIEFjwyuZs/why-ocular-therapeutix-inc-jumped-higher-today-cm746591","summary":"What happened Ocular Therapeutix NASDAQ OCUL closed up 17 7 today after Cantor Fitzgerald initiated coverage on the biotech with an overweight rating and a price target of 35 Image source Getty Images So what Analyst Elemer Piros is excited about"},{"title":"Why Ocular Therapeutix Inc Jumped Higher Today","publication_date":"2017-02-10 21:30:57 +0000","url":"http://www.fool.com/investing/2017/02/10/why-ocular-therapeutix-inc-jumped-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2","summary":"Why Ocular Therapeutix Inc Jumped Higher Today"},{"title":"Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences","publication_date":"2017-02-09 21:05:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutixtm-present-three-upcoming-210500128.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye,"},{"title":"SV Life Sciences Advisers, LLC Buys KalVista Pharmaceuticals, Sells Raptor Pharmaceutical","publication_date":"2017-02-08 09:17:03 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CFilzlAQTgo/sv-life-sciences-advisers-llc-buys-kalvista-pharmaceuticals-sells-raptor-pharmaceutical-cm744623","summary":"SV Life Sciences Advisers LLC New Purchases KALV Reduced Positions OCUL Sold Out RPTP New Purchases KALV New Purchases KALV Reduced Positions OCUL Reduced Positions OCUL Sold Out RPTP Sold Out"},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State","publication_date":"2017-01-25 21:32:10 +0000","url":"http://biz.yahoo.com/e/170125/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State"},{"title":"ETFs with exposure to Ocular Therapeutix, Inc. : January 25, 2017","publication_date":"2017-01-25 18:27:55 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-january-25-2017/","summary":"ETFs with exposure to Ocular Therapeutix, Inc. : January 25, 2017"},{"title":"Gainers & Losers Of The Day: GNVC, NVIV, CLRB. AQB, BIOA...","publication_date":"2017-01-25 00:26:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7IkfIqdddxg/gainers--losers-of-the-day-gnvc-nviv-clrb-aqb-bioa-20170125-00009","summary":"Gainers & Losers Of The Day: GNVC, NVIV, CLRB. AQB, BIOA..."},{"title":"Tuesday Sector Laggards: Drugs, Waste Management Stocks","publication_date":"2017-01-24 20:31:45 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h7EIGTayCLQ/tuesday-sector-laggards-drugs-waste-management-stocks-cm737586","summary":"In trading on Tuesday drugs shares were relative laggards down on the day by about 0 6 Helping drag down the group were shares of Ocular Therapeutix OCUL off about 9 and shares of Novan NOVN off about 6 7 on the day Also lagging the market Tuesday are waste"},{"title":"Ocular Therapeutics Sinks Following Secondary Offering","publication_date":"2017-01-24 20:13:59 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutics-sinks-following-secondary-201359317.html","summary":"Ocular Therapeutics Sinks Following Secondary Offering"},{"title":"Health Care Sector Update for 01/24/2017: OCUL,RMD,BIOA","publication_date":"2017-01-24 19:31:13 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5dOQlQnl7w0/health-care-sector-update-for-01242017-oculrmdbioa-cm737557","summary":"Top Health Care StocksTop Health Care Stocks JNJ 1 69 JNJ 1 69 PFE 1 14 PFE 1 14 MRK 0 17 MRK 0 17 ABT 1 04 ABT 1 04 AMGN 0 75 AMGN 0 75 Health care stocks were the lone industry sector in the S amp P 500 declining Tuesday with the NYSE Health Care Index dropping 0 7 while"},{"title":"Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock","publication_date":"2017-01-24 13:00:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-inc-announces-pricing-130000530.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. announced today the pricing of a registered underwritten public offering of 3,571,429 shares of its common stock at a public offering price of $7.00 per share pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission ."},{"title":"Ocular Therapeutix, Inc. Announces Public Offering of Common Stock","publication_date":"2017-01-23 21:01:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-inc-announces-public-210100203.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. announced today that it has commenced a registered underwritten public offering of $25 million of shares of its common stock pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission ."},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events","publication_date":"2017-01-23 13:26:20 +0000","url":"http://biz.yahoo.com/e/170123/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events"},{"title":"Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery","publication_date":"2017-01-23 13:15:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-resubmits-nda-dextenza-131500560.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has resubmitted a New Drug Application to the U.S."},{"title":"ETFs with exposure to Ocular Therapeutix, Inc. : January 9, 2017","publication_date":"2017-01-09 18:53:40 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-january-9-2017/","summary":"ETFs with exposure to Ocular Therapeutix, Inc. : January 9, 2017"},{"title":"6 Major FDA Decisions and Biopharma Catalysts Coming in January and February","publication_date":"2017-01-06 15:25:51 +0000","url":"http://finance.yahoo.com/news/6-major-fda-decisions-biopharma-152551867.html","summary":"6 Major FDA Decisions and Biopharma Catalysts Coming in January and February"},{"title":"Ocular (OCUL) Reports Positive Phase III Data on Eye Drug","publication_date":"2017-01-05 16:39:29 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t_8-mg02eRk/ocular-ocul-reports-positive-phase-iii-data-on-eye-drug-cm729808","summary":"Shares of Ocular Therapeutix Inc OCUL were up 3 following the company s announcement of positive results from its third phase III trial on lead pipeline candidate 160 Dextenza 0 4 mg for the treatment of post surgical ocular inflammation and pain Notably Ocular has outperformed"},{"title":"Ocular (OCUL) Reports Positive Phase III Data on Eye Drug","publication_date":"2017-01-05 14:40:02 +0000","url":"http://finance.yahoo.com/news/ocular-ocul-reports-positive-phase-144002716.html","summary":"Ocular (OCUL) Reports Positive Phase III Data on Eye Drug"},{"title":"Ocular Therapeutix Pulls Back Off Early Highs But Remains Positive","publication_date":"2017-01-04 14:00:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pGnE-otwNkw/ocular-therapeutix-pulls-back-off-early-highs-but-remains-positive-20170104-00906","summary":"Ocular Therapeutix Pulls Back Off Early Highs But Remains Positive"},{"title":"Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™","publication_date":"2017-01-04 13:33:18 +0000","url":"http://www.publicnow.com/view/5E7320396AAFAB4FD9C427DA54FC70FC418C9B4B","summary":"[at noodls] - Statistically significant secondary endpoint of absence of ocular flare confirms further evidence of reduction of inflammation BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 4, 2017-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), ..."},{"title":"Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™","publication_date":"2017-01-04 13:00:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-announces-additional-successful-130000823.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced additional positive secondary endpoint results from its most recent successful phase 3 clinical trial of DEXTENZA™ 0.4 mg, for the treatment of post-surgical ocular inflammation and pain."},{"title":"ETFs with exposure to Ocular Therapeutix, Inc. : December 30, 2016","publication_date":"2016-12-30 16:18:54 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-december-30-2016/","summary":"ETFs with exposure to Ocular Therapeutix, Inc. : December 30, 2016"},{"title":"7 Key FDA Decisions and Catalysts Expected in January and February","publication_date":"2016-12-30 12:45:32 +0000","url":"http://247wallst.com/healthcare-business/2016/12/30/7-key-fda-decisions-and-catalysts-expected-in-january-and-february/","summary":"7 Key FDA Decisions and Catalysts Expected in January and February"},{"title":"How Ocular Therapeutix Inc (OCUL) Stacks Up Against Its Peers","publication_date":"2016-12-16 04:50:38 +0000","url":"http://www.insidermonkey.com/blog/how-ocular-therapeutix-inc-ocul-stacks-up-against-its-peers-510998/","summary":"How Ocular Therapeutix Inc (OCUL) Stacks Up Against Its Peers"},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events","publication_date":"2016-12-14 21:38:32 +0000","url":"http://biz.yahoo.com/e/161214/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events"},{"title":"ETFs with exposure to Ocular Therapeutix, Inc. : December 8, 2016","publication_date":"2016-12-08 17:53:17 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-december-8-2016/","summary":"ETFs with exposure to Ocular Therapeutix, Inc. : December 8, 2016"},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State","publication_date":"2016-11-30 11:05:13 +0000","url":"http://biz.yahoo.com/e/161130/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State"},{"title":"ETFs with exposure to Ocular Therapeutix, Inc. : November 28, 2016","publication_date":"2016-11-28 17:23:43 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-november-28-2016/","summary":"ETFs with exposure to Ocular Therapeutix, Inc. : November 28, 2016"},{"title":"Stocks Pull Back Following Recent Upward Trend - U.S. Commentary","publication_date":"2016-11-28 16:22:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EKbjuwCY_Ug/stocks-pull-back-following-recent-upward-trend--us-commentary-20161128-00816","summary":"Stocks Pull Back Following Recent Upward Trend - U.S. Commentary"},{"title":"Stocks Stuck In Negative Territory In Mid-Day Trading - U.S. Commentary","publication_date":"2016-11-28 11:57:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IGuhb8uiXkk/stocks-stuck-in-negative-territory-in-midday-trading--us-commentary-20161128-00597","summary":"Stocks Stuck In Negative Territory In Mid-Day Trading - U.S. Commentary"},{"title":"Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016","publication_date":"2016-11-23 15:15:32 +0000","url":"http://www.capitalcube.com/blog/index.php/ocular-therapeutix-inc-ocul-us-earnings-analysis-q3-2016-by-the-numbers-november-23-2016/","summary":"Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016"},{"title":"OCULAR THERAPEUTIX, INC Financials","publication_date":"2016-11-17 18:04:24 +0000","url":"http://finance.yahoo.com/q/is?s=ocul","summary":"OCULAR THERAPEUTIX, INC Financials"},{"title":"FDA Snubs DVAX, Keep An Eye On OCUL, It''s All Green For BLUE","publication_date":"2016-11-15 01:21:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5kdvVrziyXY/fda-snubs-dvax-keep-an-eye-on-ocul-its-all-green-for-blue-20161115-00027","summary":"FDA Snubs DVAX, Keep An Eye On OCUL, It''s All Green For BLUE"},{"title":"FDA Snubs DVAX, Keep An Eye On OCUL, It's All Green For BLUE","publication_date":"2016-11-15 01:21:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_6PcBqSY1LI/fda-snubs-dvax-keep-an-eye-on-ocul-its-all-green-for-blue-20161115-00028","summary":"FDA Snubs DVAX, Keep An Eye On OCUL, It's All Green For BLUE"},{"title":"Notable Monday Option Activity: PBYI, OCUL, REGN","publication_date":"2016-11-14 22:28:59 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WUnVjKRfg6o/notable-monday-option-activity-pbyi-ocul-regn-cm709018","summary":"Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 6 622 contracts has been traded thus far today a contract volume which is representative of approximately 662"},{"title":"Ocular Therapeutix surges 14% on positive early clinical trial results","publication_date":"2016-11-14 13:27:34 +0000","url":"http://www.marketwatch.com/News/Story/Story.aspx?guid=E3840D42-0736-4155-8BAE-87B8CC0D9CB0&siteid=yhoof2","summary":"Ocular Therapeutix surges 14% on positive early clinical trial results"},{"title":"Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™","publication_date":"2016-11-14 12:17:10 +0000","url":"http://www.publicnow.com/view/7517A269454E2A126B06DF097D7898E40CC43172","summary":"[at noodls] - Conference Call Today at 8:30 am Eastern Time BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 14, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization ..."},{"title":"Edited Transcript of OCUL earnings conference call or presentation 9-Nov-16 1:30pm GMT","publication_date":"2016-11-10 04:53:39 +0000","url":"http://finance.yahoo.com/news/edited-transcript-ocul-earnings-conference-045339894.html","summary":"Edited Transcript of OCUL earnings conference call or presentation 9-Nov-16 1:30pm GMT"},{"title":"ADAP Surges As FDA Lifts Clinical Hold, OCUL Catches Eyes, RegeneRx On The Rise","publication_date":"2016-11-10 01:57:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dQSDgHm_C-g/adap-surges-as-fda-lifts-clinical-hold-ocul-catches-eyes-regenerx-on-the-rise-20161110-00064","summary":"ADAP Surges As FDA Lifts Clinical Hold, OCUL Catches Eyes, RegeneRx On The Rise"},{"title":"Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences","publication_date":"2016-11-09 21:21:23 +0000","url":"http://www.publicnow.com/view/EB0DDECAEFBD690F170A079189D3B682625DD428","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 9, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update","publication_date":"2016-11-09 12:19:07 +0000","url":"http://www.publicnow.com/view/4FE7765B8C6D45494EEB4D15127700163AD103CD","summary":"[at noodls] - Preparing to Resubmit NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery to FDA by the End of 2016 Began Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained ..."},{"title":"Ocular Therapeutix reports 3Q loss","publication_date":"2016-11-09 12:16:45 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-3q-loss-121645124.html","summary":"Ocular Therapeutix reports 3Q loss"},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E","publication_date":"2016-11-09 12:08:59 +0000","url":"http://biz.yahoo.com/e/161109/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"},{"title":"Q3 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open","publication_date":"2016-11-09 12:07:06 +0000","url":"http://biz.yahoo.com/research/earncal/20161109.html?t=ocul","summary":"Q3 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open"},{"title":"Ocular Therapeutix™ to Hold Third Quarter 2016 Financial Results Conference Call on Wednesday, November 9, 2016","publication_date":"2016-11-02 12:10:14 +0000","url":"http://www.publicnow.com/view/AF67AB9350DF21CF73F1160BE9C3F8F5B5092B39","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 2, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer","publication_date":"2016-10-20 12:19:06 +0000","url":"http://www.publicnow.com/view/5164756D1046F4395E323AFC05FD71CEBBEF46B9","summary":"[at noodls] - BEDFORD, Mass--(BUSINESS WIRE)--Oct. 20, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron","publication_date":"2016-10-14 16:42:44 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n17cqIkYVZ8/oculars-ocul-stock-jumps-on-collaboration-with-regeneron-cm693506","summary":"Regeneron Pharmaceuticals Inc REGN and Ocular Therapeutix Inc OCUL announced a strategic collaboration and option and license agreement for the development of a sustained release formulation of Regeneron s Eylea aflibercept for the treatment of wet age related macular degeneration"},{"title":"Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron","publication_date":"2016-10-14 14:27:02 +0000","url":"http://finance.yahoo.com/news/oculars-ocul-stock-jumps-collaboration-142702904.html","summary":"Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron"},{"title":"Blog Coverage Ocular Therapeutix Announces a Potential 315 Million Dollar Drug Development Deal with Regeneron Pharma","publication_date":"2016-10-14 13:11:40 +0000","url":"http://news.investornetwork.com/2016/10/14/blog-coverage-ocular-therapeutix-announces-a-potential-315-million-dollar-drug-development-deal-with-regeneron-pharma/?1=1&1476450700","summary":"Blog Coverage Ocular Therapeutix Announces a Potential 315 Million Dollar Drug Development Deal with Regeneron Pharma"},{"title":"Close Update: Downbeat Chinese Trade Data Weighs on Wall Street","publication_date":"2016-10-13 21:00:50 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uBJSnMiS2R4/close-update-downbeat-chinese-trade-data-weighs-on-wall-street-cm693161","summary":"Stocks closed with modest losses on Thursday but off their worst levels of the day when disappointing trade data from China rekindled worries about the world s second largest economy and a 43 year low in initial jobless claims raised the odds for a December rate hike The Dow was trading"},{"title":"Regeneron, Ocular to Develop Eye Drug (REGN, OCUL)","publication_date":"2016-10-13 20:13:00 +0000","url":"http://www.investopedia.com/news/regeneron-ocular-enter-315m-deal-regn-ocul/?partner=YahooSA","summary":"Regeneron, Ocular to Develop Eye Drug (REGN, OCUL)"},{"title":"Midday Update: Wall Street Spooked by Downbeat Chinese Trade Data","publication_date":"2016-10-13 17:20:59 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cIy_gSJJ2X4/midday-update-wall-street-spooked-by-downbeat-chinese-trade-data-cm693039","summary":"Stocks continue to trade with sizable losses on Thursday after investors fled risky assets in the wake of disappointing Chinese trade data and a 43 year low in new U S unemployment claims The Dow Jones Industrial Average and S amp P 500 fell to their lowest levels in more than 3 months on"},{"title":"Regeneron: Today is the Greatest Day I've Ever Known","publication_date":"2016-10-13 16:51:00 +0000","url":"http://blogs.barrons.com/stockstowatchtoday/2016/10/13/regeneron-today-is-the-greatest-day-ive-ever-known/?mod=yahoobarrons&ru=yahoo","summary":"Regeneron: Today is the Greatest Day I've Ever Known"},{"title":"Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal","publication_date":"2016-10-13 16:05:00 +0000","url":"https://www.thestreet.com/story/13852486/1/ocular-therapeutix-ocul-stock-soars-on-regeneron-deal.html?puc=yahoo&cm_ven=YAHOO","summary":"Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal"},{"title":"Here’s Why Amazon, Alphabet, Ocular Therapeutix, and Two Other Stocks Are Trending on Thursday","publication_date":"2016-10-13 15:16:29 +0000","url":"http://www.insidermonkey.com/blog/heres-why-amazon-alphabet-ocular-therapeutix-and-two-other-stocks-are-trending-on-thursday-481049/","summary":"Here’s Why Amazon, Alphabet, Ocular Therapeutix, and Two Other Stocks Are Trending on Thursday"},{"title":"Bedford's Ocular Therapeutix inks potential $315M deal with Regeneron","publication_date":"2016-10-13 14:48:46 +0000","url":"http://www.bizjournals.com/boston/blog/bioflash/2016/10/bedfords-ocular-therapeutix-inks-potential-315m.html?ana=yahoo","summary":"Bedford's Ocular Therapeutix inks potential $315M deal with Regeneron"},{"title":"Stock Futures Turn Defensive as China Trade Disappoints, Initial Claims Fall to 43-Year Low","publication_date":"2016-10-13 13:41:06 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4CTS09VXPv0/stock-futures-turn-defensive-as-china-trade-disappoints-initial-claims-fall-to-43-year-low-cm692721","summary":"U S stock futures were building on earlier losses as the number of Americans filing unemployment claims fell to a 43 year low and China s disappointing trade data rekindled investors concerns about the state of the world s second largest economy U S stock futures were building on earlier"},{"title":"Ocular Therapeutix stock up 26% on $10 mln Regeneron drug development deal","publication_date":"2016-10-13 13:22:12 +0000","url":"http://www.marketwatch.com/News/Story/Story.aspx?guid=6CE8029F-A8F0-4F45-9868-F39708EDB6FB&siteid=yhoof2","summary":"Ocular Therapeutix stock up 26% on $10 mln Regeneron drug development deal"},{"title":"Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration","publication_date":"2016-10-13 13:05:59 +0000","url":"http://247wallst.com/healthcare-business/2016/10/13/why-ocular-therapeutix-is-winning-big-with-its-regeneron-collaboration/","summary":"Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration"},{"title":"Pre-Market Most Active for Oct 13, 2016 : ERIC, SNY, LYG, OCUL, NOK, MT, XIV, RBS, MSFT, QQQ, FCX, TVIX","publication_date":"2016-10-13 13:00:28 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tCunonxOO0E/pre-market-most-active-for-oct-13-2016-eric-sny-lyg-ocul-nok-mt-xiv-rbs-msft-qqq-fcx-tvix-cm692711","summary":"The NASDAQ 100 Pre Market Indicator is down 15 22 to 4 804 41 The total Pre Market volume is currently 10 104 006 shares traded The following are the most active stocks for the pre market session Ericsson ERIC is 0 04 at 5 59 with 2 684 667 shares traded"},{"title":"Ocular Therapeutix Inc Conference Call to Provide Updates on Back of the Eye Programs scheduled for 8:30 am ET today","publication_date":"2016-10-13 12:30:00 +0000","url":"http://biz.yahoo.com/cc/4/154184.html","summary":"Ocular Therapeutix Inc Conference Call to Provide Updates on Back of the Eye Programs scheduled for 8:30 am ET today"},{"title":"Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases","publication_date":"2016-10-13 11:20:07 +0000","url":"http://www.publicnow.com/view/D52CC833F4191DE1B386DCB8D3BE907D2D4952BD","summary":"[at noodls] - Sustained Release Formulation Has Potential to Significantly Advance Current Standard of Care by Reducing Injection Frequency in the Treatment of Wet AMD Ocular Therapeutix Eligible to Receive up to $305 ..."},{"title":"Ocular Therapeutix™ Outlines Development Strategy for Its Sustained Release Intravitreal Depots to Address Serious Retinal Diseases","publication_date":"2016-10-13 11:20:07 +0000","url":"http://www.publicnow.com/view/2F5EFEEDCBAAAC50C6A9D909D0C54CDCDF541672","summary":"[at noodls] - New Strategic Collaboration with Regeneron to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases Ocular Therapeutix Selected to Present ..."},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement","publication_date":"2016-10-13 11:07:06 +0000","url":"http://biz.yahoo.com/e/161013/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement"},{"title":"Ocular Therapeutix and Regeneron Sign Research Agreement","publication_date":"2016-10-13 08:59:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qS3xlEgFBh4/ocular-therapeutix-and-regeneron-sign-research-agreement-20161013-00536","summary":"Ocular Therapeutix and Regeneron Sign Research Agreement"},{"title":"Ocular Therapeutix Signs Strategic Collaboration With Regeneron Pharma","publication_date":"2016-10-13 07:29:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WzvVOSjCuJk/ocular-therapeutix-signs-strategic-collaboration-with-regeneron-pharma-20161013-00290","summary":"Ocular Therapeutix Signs Strategic Collaboration With Regeneron Pharma"},{"title":"ETF’s with exposure to Ocular Therapeutix, Inc. : October 6, 2016","publication_date":"2016-10-06 14:07:19 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-october-6-2016/","summary":"ETF’s with exposure to Ocular Therapeutix, Inc. : October 6, 2016"},{"title":"Ocular Begins Enrollment in Phase III Trial on Glaucoma Drug","publication_date":"2016-10-05 15:47:51 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/weu9xfbGbTg/ocular-begins-enrollment-in-phase-iii-trial-on-glaucoma-drug-cm689083","summary":"Ocular Therapeutix Inc OCUL announced the enrollment of the first patient in one of the two planned phase III clinical trials on its pipeline candidate OTX TP sustained release travoprost for the treatment of glaucoma and ocular hypertension The U S based prospective"},{"title":"Ocular Begins Enrollment in Phase III Trial on Glaucoma Drug","publication_date":"2016-10-05 14:02:02 +0000","url":"http://finance.yahoo.com/news/ocular-begins-enrollment-phase-iii-140202968.html","summary":"Ocular Begins Enrollment in Phase III Trial on Glaucoma Drug"},{"title":"CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes","publication_date":"2016-10-05 01:04:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qCD762Mut_8/catb-data-pushed-back-to-q1-smmt-at-peak-trib-pounded-otic-hits-right-notes-20161005-00016","summary":"CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes"},{"title":"Ocular Therapeutix™ Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension","publication_date":"2016-10-04 20:38:05 +0000","url":"http://www.publicnow.com/view/50AD97936DE4B6952FFBF70A1C8EA97489512771","summary":"[at noodls] - Phase 3 study design to compare OTX-TP with placebo inserts; no timolol validation arm required Refined product design shows significant improvement in patient retention over 3-month duration BEDFORD, ..."},{"title":"Lifshitz & Miller Law Firm Announces Investigation of AECOM, American Farmland Company, Centene Corp., Cepheid, Cray Inc., Echo Global Logistics, Inc., Ocular Therapeutix, Inc., and Pure Storage, Inc.","publication_date":"2016-09-13 19:18:00 +0000","url":"http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-191800344.html","summary":"[PR Newswire] - NEW YORK, Sept. 13, 2016 /PRNewswire/ -- AECOM (ACM) Lifshitz & Miller announces investigation on behalf of AECOM investors. Specifically, Spruce Point Capital Management published a report stating that ..."},{"title":"ETF’s with exposure to Ocular Therapeutix, Inc. : September 13, 2016","publication_date":"2016-09-13 14:46:22 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-september-13-2016/","summary":"ETF’s with exposure to Ocular Therapeutix, Inc. : September 13, 2016"},{"title":"Ocular Therapeutix™ to Participate in the Morgan Stanley Global Healthcare Conference","publication_date":"2016-08-31 20:05:00 +0000","url":"http://finance.yahoo.com/news/ocular-therapeutix-participate-morgan-stanley-200500372.html","summary":"[Business Wire] - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 4:15 p.m."},{"title":"ETF’s with exposure to Ocular Therapeutix, Inc. : August 29, 2016","publication_date":"2016-08-29 15:54:38 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-august-29-2016/","summary":"ETF’s with exposure to Ocular Therapeutix, Inc. : August 29, 2016"},{"title":"ETF’s with exposure to Ocular Therapeutix, Inc. : August 16, 2016","publication_date":"2016-08-16 16:31:24 +0000","url":"http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-ocular-therapeutix-inc-august-16-2016/","summary":"ETF’s with exposure to Ocular Therapeutix, Inc. : August 16, 2016"},{"title":"Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016","publication_date":"2016-08-15 17:43:07 +0000","url":"http://www.capitalcube.com/blog/index.php/ocular-therapeutix-inc-ocul-us-earnings-analysis-q2-2016-by-the-numbers-august-15-2016/","summary":"Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016"},{"title":"5 Biohealth Stocks Rising 10% or More on News","publication_date":"2016-08-11 17:05:41 +0000","url":"http://247wallst.com/healthcare-business/2016/08/11/5-biohealth-stocks-rising-10-or-more-on-news/","summary":"5 Biohealth Stocks Rising 10% or More on News"},{"title":"Coverage initiated on Ocular Therapeutix by JMP Securities","publication_date":"2016-08-11 11:34:25 +0000","url":"http://finance.yahoo.com/q/ud?s=OCUL","summary":"Coverage initiated on Ocular Therapeutix by JMP Securities"},{"title":"Edited Transcript of OCUL earnings conference call or presentation 9-Aug-16 12:30pm GMT","publication_date":"2016-08-09 17:56:55 +0000","url":"http://finance.yahoo.com/news/edited-transcript-ocul-earnings-conference-175655066.html","summary":"Edited Transcript of OCUL earnings conference call or presentation 9-Aug-16 12:30pm GMT"},{"title":"Ocular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today","publication_date":"2016-08-09 12:30:00 +0000","url":"http://biz.yahoo.com/cc/0/153460.html","summary":"Ocular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today"},{"title":"Ocular Therapeutix reports 2Q loss","publication_date":"2016-08-09 11:53:35 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-2q-loss-115335303.html","summary":"Ocular Therapeutix reports 2Q loss"},{"title":"Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results and Provides Corporate Update","publication_date":"2016-08-09 11:50:04 +0000","url":"http://www.publicnow.com/view/A02E3EB01B4F79CD4CE7892EDBA1EEED0EAF8B3A","summary":"[at noodls] - Conference call today at 8:30 am Eastern Time BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 9, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization ..."},{"title":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E","publication_date":"2016-08-09 11:37:37 +0000","url":"http://biz.yahoo.com/e/160809/ocul8-k.html","summary":"OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"},{"title":"Q2 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open","publication_date":"2016-08-09 11:07:03 +0000","url":"http://biz.yahoo.com/research/earncal/20160809.html?t=ocul","summary":"Q2 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open"},{"title":"A Handful of Biotech Stocks Plunge After Disappointing Results","publication_date":"2016-08-08 20:51:05 +0000","url":"http://finance.yahoo.com/news/handful-biotech-stocks-plunge-disappointing-205105977.html","summary":"A Handful of Biotech Stocks Plunge After Disappointing Results"},{"title":"These 7 Stocks Under $10 Are Making Big Moves Higher","publication_date":"2016-08-05 12:56:00 +0000","url":"https://www.thestreet.com/story/13666340/1/these-7-stocks-under-10-are-making-big-moves-higher.html?puc=yahoo&cm_ven=YAHOO","summary":"These 7 Stocks Under $10 Are Making Big Moves Higher"},{"title":"Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)","publication_date":"2016-08-05 12:24:08 +0000","url":"http://www.publicnow.com/view/888B8DE4600A854C2F54D567E06EBB05AC945893","summary":"[at noodls] - Presentation to highlight preclinical data supporting the Company's proprietary sustained release technology for intravitreal injections BEDFORD, Mass--(BUSINESS WIRE)--Aug. 5, 2016-- Ocular Therapeutix, ..."},{"title":"Why is Ocular Therapeutics (OCUL) Surging 36% Today?","publication_date":"2016-08-04 21:52:39 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y578HfLyf-8/why-is-ocular-therapeutics-ocul-surging-36-today-cm660741","summary":"Ocular Therapeutics OCUL is up 34.8% in afternoon trading after announcing that the FDA's concerns regarding the company's New Drug Application (NDA) appear to have been addressed. Based in Bedford, MA, OCUL is a biopharmaceutical company that focuses on"},{"title":"Why is Ocular Therapeutics (OCUL) Surging 36% Today?","publication_date":"2016-08-04 19:49:07 +0000","url":"http://finance.yahoo.com/news/why-ocular-therapeutics-ocul-surging-194907426.html","summary":"Why is Ocular Therapeutics (OCUL) Surging 36% Today?"},{"title":"Midday Update: Stocks Turn Neutral Ahead of Labor Market Report","publication_date":"2016-08-04 17:29:07 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Sg5BqmvGqc/midday-update-stocks-turn-neutral-ahead-of-labor-market-report-cm660580","summary":"The Dow Jones Industrial Average was straddling the flat line Thursday while the S&P 500 and Nasdaq were clinging onto modest gains as the excitement that followed the Bank of England's rate cut evaporated and investors squared up positions"},{"title":"Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns","publication_date":"2016-08-04 16:38:00 +0000","url":"https://www.thestreet.com/story/13665332/1/ocular-therapeutix-ocl-stock-soars-fda-corrective-actions-address-concerns.html?puc=yahoo&cm_ven=YAHOO","summary":"Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns"},{"title":"Ocular Therapeutix™ Provides Update on NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain","publication_date":"2016-08-03 20:12:11 +0000","url":"http://www.publicnow.com/view/7A8524F1605187B4B5B8BF5995D53E9F0CA40089","summary":"[at noodls] - One outstanding item remains pertaining to manufacturing process and controls BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 3, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused ..."},{"title":"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm","publication_date":"2016-08-03 10:35:00 +0000","url":"http://finance.yahoo.com/news/important-shareholder-alert-khang-khang-103500457.html","summary":"[Business Wire] - Khang & Khang LLP announces that it is investigating claims against Ocular Therapeutix, Inc. concerning possible violations of federal securities laws."},{"title":"Ocular Therapeutix™ to Report Second Quarter 2016 Financial Results","publication_date":"2016-08-02 20:32:07 +0000","url":"http://www.publicnow.com/view/C8FE1C57822EA80C1F5D1FE94F40770F1B57B208","summary":"[at noodls] - BEDFORD, Mass--(BUSINESS WIRE)--Aug. 2, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocular Therapeutix, Inc. - OCUL","publication_date":"2016-08-02 18:16:00 +0000","url":"http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-181600042.html","summary":"[Accesswire] - NEW YORK, NY / ACCESSWIRE / August 2, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Ocular Therapeutix, Inc. (\"Ocular\" or the \"Company\") (NASDAQ: OCUL). Such ..."},{"title":"IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ocular Therapeutix, Inc. and Advises Investors with Losses to Contact the Firm","publication_date":"2016-08-01 14:43:00 +0000","url":"http://finance.yahoo.com/news/important-shareholder-alert-lundin-law-144300840.html","summary":"[Business Wire] - Lundin Law PC announces it is investigating claims against Ocular Therapeutix concerning possible violations of federal securities laws."},{"title":"Glancy Prongay & Murray Commences Investigation on Behalf of Ocular Therapeutix, Inc. Investors","publication_date":"2016-07-29 19:31:00 +0000","url":"http://finance.yahoo.com/news/glancy-prongay-murray-commences-investigation-193100006.html","summary":"[Business Wire] - Glancy Prongay & Murray LLP announces an investigation on behalf of investors of Ocular Therapeutix, Inc. concerning the Company and its officers’ possible violations of federal securities laws."},{"title":"IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Ocular Therapeutix, Inc. And Advises Investors With Losses To Contact The Firm","publication_date":"2016-07-27 22:14:00 +0000","url":"http://finance.yahoo.com/news/important-shareholder-notice-goldberg-law-221400891.html","summary":"[Business Wire] - Goldberg Law PC announces that it is investigating claims of potential misrepresentations by Ocular Therapeutix, Inc. ."},{"title":"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Ocular Therapeutix Inc.","publication_date":"2016-07-27 20:02:00 +0000","url":"http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-200200936.html","summary":"[Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Ocular Therapeutix Inc. concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors."},{"title":"Good News For GNVC, ACRS On Track, TBRA Tanks, FDA Says No To OCUL","publication_date":"2016-07-26 00:47:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oyqpXLRIxpo/good-news-for-gnvc-acrs-on-track-tbra-tanks-fda-says-no-to-ocul-20160726-00005","summary":"Good News For GNVC, ACRS On Track, TBRA Tanks, FDA Says No To OCUL"},{"title":"Pre-Market Most Active for Jul 25, 2016 : AZN, S, YHOO, SMFG, TKC, SNY, MU, RDS/B, OCUL, XIV, FB, BLPH","publication_date":"2016-07-25 13:07:04 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OUthqxEwTGg/pre-market-most-active-for-jul-25-2016-azn-s-yhoo-smfg-tkc-sny-mu-rdsb-ocul-xiv-fb-blph-cm653932","summary":"The NASDAQ 100 Pre Market Indicator is up 2.45 to 4,668.52. The total Pre Market volume is currently 5,530,003 shares traded. The following are the most active stocks for the pre market session Astrazeneca PLC ( AZN ) is"},{"title":"Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain","publication_date":"2016-07-25 12:08:00 +0000","url":"http://www.publicnow.com/view/6A852197AC4F47AFF16941272D22C145094127F1","summary":"[at noodls] - No efficacy or safety issues raised by FDA Outstanding items pertain to manufacturing process and controls BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 25, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical ..."},{"title":"Ocular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference","publication_date":"2016-07-06 12:11:09 +0000","url":"http://www.publicnow.com/view/B55B90A32DDE0E3522913560B8407FADE7D37F34","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 6, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Biotech Stocks Facing FDA Decision In July","publication_date":"2016-06-30 06:19:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-eOv98I5puw/biotech-stocks-facing-fda-decision-in-july-20160630-00140","summary":"Biotech Stocks Facing FDA Decision In July"},{"title":"ADMP Snubbed Again, OCUL, DNAI Skid On Trial Data, AGN Gets FDA Nod. SRPT Abuzz","publication_date":"2016-06-07 01:56:00 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R0lid86hsxY/admp-snubbed-again-ocul-dnai-skid-on-trial-data-agn-gets-fda-nod-srpt-abuzz-20160607-00028","summary":"ADMP Snubbed Again, OCUL, DNAI Skid On Trial Data, AGN Gets FDA Nod. SRPT Abuzz"},{"title":"Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences","publication_date":"2016-06-02 20:25:04 +0000","url":"http://www.publicnow.com/view/AD0804E63353DB15BD968607D09D1ADCD6174F7A","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix™ Reports First Quarter 2016 Financial Results and Provides Corporate Update","publication_date":"2016-05-10 11:18:10 +0000","url":"http://www.publicnow.com/view/43F8C7DAEB52990BE18028FF8401E3A036ECB89A","summary":"[at noodls] - PDUFA target action date of July 24, 2016 for DEXTENZA™ NDA for the treatment of post-surgical ocular pain Second Phase 3 clinical trial for DEXTENZA for the treatment of allergic conjunctivitis fully ..."},{"title":"Ocular Therapeutix reports 1Q loss","publication_date":"2016-05-10 11:08:38 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-1q-loss-110838283.html","summary":"Ocular Therapeutix reports 1Q loss"},{"title":"Ocular Therapeutix™ to Report First Quarter 2016 Financial Results","publication_date":"2016-05-03 20:20:05 +0000","url":"http://www.publicnow.com/view/BE7A2511FB59D400FAE51F0BEBFA28AE62C0C51B","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--May 3, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular TherapeutixTM Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension","publication_date":"2016-04-27 20:27:34 +0000","url":"http://www.publicnow.com/view/C63853F1111B54048B7668A2B45CE26F79B2F2FF","summary":"[at noodls] - First Phase 3 trial expected to commence in the third quarter of 2016 Trial design to evaluate OTX-TP using placebo as comparator; no timolol validation arm required BEDFORD, Mass.--(BUSINESS WIRE)--Apr. ..."},{"title":"Analysts Anticipate IWV To Hit $133","publication_date":"2016-04-13 12:58:55 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pyw0wd7DtnI/analysts-anticipate-iwv-to-hit-133-cm605628","summary":"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"},{"title":"Can The Uptrend Continue for Ocular Therapeutix (OCUL)?","publication_date":"2016-04-05 16:06:16 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ljx5WONQeo4/can-the-uptrend-continue-for-ocular-therapeutix-ocul-cm601894","summary":"Investors certainly have to be happy with Ocular Therapeutix Inc OCUL and its short term performance. After all, the stock has jumped by 13.2% in the past 4 weeks, and it is also above its 20 Day Simple Moving"},{"title":"Ocular TherapeutixTM to Host Investor Day on April 6, 2016","publication_date":"2016-03-28 20:22:35 +0000","url":"http://www.publicnow.com/view/572D0AF16603945811C5606FB6A81B994C489306","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 28, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix reports 4Q loss","publication_date":"2016-03-10 12:15:37 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-4q-loss-121537856.html","summary":"Ocular Therapeutix reports 4Q loss"},{"title":"Closing Update: Stocks Extend Rally to Third Day Supported by Rising Oil Price, Improving Factory Output","publication_date":"2016-02-17 21:43:28 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_e5k3_Yoi5c/closing-update-stocks-extend-rally-to-third-day-supported-by-rising-oil-price-improving-factory-output-cm581191","summary":"Stocks rose for a third day in a row Wednesday, posting their best gains so far in 2016 as crude oil continued its recovery after minutes from the most recent Federal Open Markets Committee meeting indicated Federal Reserve policy"},{"title":"Health Care Sector Update for 02/17/2016: FLXN,OCUL,CPRX","publication_date":"2016-02-17 21:20:12 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q6lKJnMw3hY/health-care-sector-update-for-02172016-flxnoculcprx-cm581186","summary":"Top Health Care Stocks JNJ +0.14% PZE 0.39% MRK +1.20% ABT +1.59% AMGN +2.28% Health care stocks were mostly higher today, with the NYSE Health Care Index rising about 1.2% while shares of health care companies in the S&P"},{"title":"Health Care Sector Update for 02/17/2016: CERN,OCUL,CPRX","publication_date":"2016-02-17 18:00:10 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OzFiHcEC7oI/health-care-sector-update-for-02172016-cernoculcprx-cm581013","summary":"Top Health Care Stocks JNJ +0.17% PZE 0.02% MRK +1.33% ABT +1.39% AMGN +2.22% Health care stocks were mostly higher, with the NYSE Health Care Index rising about 1.0% while shares of health care companies in the S&P 500"},{"title":"Ocular TherapeutixTM Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer","publication_date":"2016-01-11 12:17:19 +0000","url":"http://www.noodls.com/view/B67ACDD5F1EC82071B57F18635FD6C2631D8CF25","summary":"[at noodls] - --(BUSINESS WIRE)--Jan. 11, 2016-- (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced ..."},{"title":"Ocular Therapeutix (OCUL) Shares March Higher, Can It Continue?","publication_date":"2015-12-21 17:18:47 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iPDfys_GyNM/ocular-therapeutix-ocul-shares-march-higher-can-it-continue-cm557146","summary":"As of late, it has definitely been a great time to be an investor in Ocular Therapeutix Inc OCUL . The stock has moved higher by 26.2% in the past month, while it is also above its 20 Day"},{"title":"Ocular Therapeutix, Inc. (Nasdaq: OCUL) to Ring The Nasdaq Stock Market Opening Bell","publication_date":"2015-12-14 14:02:24 +0000","url":"http://www.noodls.com/view/F27FD3C49394EC684BA5149238111D9705CDD59B","summary":"[at noodls] - What: Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company creating innovative therapies for diseases and conditions of the eye, will visit the Nasdaq MarketSite in Times Square. In honor ..."},{"title":"Ocular Therapeutix™ Announces Encouraging Top-Line Results from Exploratory Phase 2 Trial for DEXTENZA™ in Patients with Inflammatory Dry Eye Disease","publication_date":"2015-12-14 12:32:24 +0000","url":"http://www.noodls.com/view/DF1CC0E0778019452DC5ABB24ACB919BB57D9D91","summary":"[at noodls] - DEXTENZA showed benefit in efficacy measure of corneal staining signs of inflammatory dry eye disease for total corneal staining change from baseline at day 30 Supportive measures of conjunctival staining ..."},{"title":"Ocular Therapeutix, Inc. (Nasdaq: OCUL) to Ring the Nasdaq Stock Market Opening Bell","publication_date":"2015-12-11 15:06:30 +0000","url":"http://www.noodls.com/view/2DECB8BF2E99301E850F91369961BAD205005904","summary":"[at noodls] - ADVISORY, Dec. 11, 2015 (GLOBE NEWSWIRE) -- What: Ocular Therapeutix, Inc. (Nasdaq:OCUL), a biopharmaceutical company creating innovative therapies for diseases and conditions of the eye, will visit the ..."},{"title":"Ocular Therapeutix™ Announces FDA Acceptance of NDA Filing for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain","publication_date":"2015-12-09 13:32:01 +0000","url":"http://www.noodls.com/view/DF89126611FB0C25A838E8BA3BE2F4BB87943C0E","summary":"[at noodls] - PDUFA target action date of July 24, 2016 DEXTENZA initial target indication comprises over 5 million ocular surgeries BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 9, 2015-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), ..."},{"title":"Ocular Begins Second Phase III Allergic Conjunctivitis Study","publication_date":"2015-11-26 20:36:11 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gf0UeQMSsU0/ocular-begins-second-phase-iii-allergic-conjunctivitis-study-cm547665","summary":"Pipeline updates are highly awaited events in the pharma biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give"},{"title":"Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference","publication_date":"2015-11-24 21:17:28 +0000","url":"http://www.noodls.com/view/C919C1CA202C8169E36E56673F451E7CA214F628","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 24, 2015-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix™ Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis","publication_date":"2015-11-24 13:33:23 +0000","url":"http://www.noodls.com/view/42F7F14A6E4E4A667412802FDA6F493935DFFBB5","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 24, 2015-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix reports 3Q loss","publication_date":"2015-11-10 21:39:46 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-reports-3q-loss-213946477.html","summary":"Ocular Therapeutix reports 3Q loss"},{"title":"Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results","publication_date":"2015-11-10 21:36:15 +0000","url":"http://www.noodls.com/view/E09A1A11D27387960B23A38099B9ED97C0F5ED8C","summary":"[at noodls] - Advances in Clinical Programs Include NDA Submission for DEXTENZA™ (sustained release dexamethasone, 0.4mg) for the Treatment of Post-Surgical Ocular Pain Results Reported for Phase 3 Allergic Conjunctivitis ..."},{"title":"Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O’Shea","publication_date":"2015-11-09 21:26:20 +0000","url":"http://www.noodls.com/view/536D11F323381449E35BF03F1E40C08C920E03CC","summary":"[at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 9, 2015-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ..."},{"title":"Ocular Therapeutix (OCUL) Enters Oversold Territory","publication_date":"2015-10-29 12:44:07 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3zS7jtrNips/ocular-therapeutix-ocul-enters-oversold-territory-cm536121","summary":"Ocular Therapeutix Inc OCUL has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking"},{"title":"Health Care Sector Update for 10/23/2015: OCUL,IG,MMSI","publication_date":"2015-10-23 20:00:16 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sphZ7V_cA1Q/health-care-sector-update-for-10232015-oculigmmsi-cm534028","summary":"Top Health Care Stocks JNJ +1.24% PZE +2.93% MRK +0.51% ABT +2.25% AMGN +2.25% Health care stocks posted big gains, with the NYSE Health Care Index jumping more than 2.5% while shares of health care companies in the S&P"},{"title":"Ocular (OCUL) Initiates Third Phase III Study on Dextenza","publication_date":"2015-10-21 22:44:05 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/amBkALvKk4Q/ocular-ocul-initiates-third-phase-iii-study-on-dextenza-cm533108","summary":"Ocular Therapeutix, Inc.OCUL announced the initiation of patient enrolment in the third phase III study on Dextenza (sustained release dexamethasone) for the treatment of post surgical ocular inflammation and pain. The prospective, multicenter, randomized, parallel arm, double masked, vehicle"},{"title":"Health Care Sector Update for 08/13/2015: OCUL, IMUC","publication_date":"2015-08-13 20:01:22 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dMrhT6Jm5Ew/health-care-sector-update-for-08132015-ocul-imuc-cm508951","summary":"Top Health care stocks JNJ 0.1% PFE +0.3% ABT 0.3% MRK +1.7% AMGN flat Health care shares were mixed in Thursday's late afternoon trading session. In health care stocks news, analysts at Morgan Stanley initiated coverage of Ocular Therapeutix"},{"title":"Ocular Therapeutix (OCUL) in Focus: Stock Goes Down 6.4% - Tale of the Tape","publication_date":"2015-04-10 16:15:56 +0000","url":"http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c_B3Lxhx7vU/ocular-therapeutix-ocul-in-focus-stock-goes-down-64-tale-of-the-tape-cm464175","summary":"Ocular Therapeutix, Inc. ( OCUL ) saw a big move in the last trading session, as the company's shares fell by over 6% on the day. The move came on pretty good volume too with far more shares changing"},{"title":"Ocular Therapeutix slumps on eye treatment study","publication_date":"2015-04-06 22:12:50 +0000","url":"http://sg.finance.yahoo.com/news/ocular-therapeutix-slumps-eye-treatment-221250857.html","summary":"Ocular Therapeutix slumps on eye treatment study"}],"result_count":149,"page_size":250,"current_page":1,"total_pages":1,"api_call_credits":1}}
]
